Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/1/e003697.full |
| _version_ | 1828136873933930496 |
|---|---|
| author | Rui Wang Antoine Italiano Shubham Pant Johann De Bono Todd M Bauer Christophe Massard Chia-Chi Lin Roberto Iacovelli Martin Gutierrez Mansoor Saleh Helen Lee Gennaro Daniele Paolo Andrea Zucali Marielle Chiron Bradley C Carthon Robin Meng Giovanni Abbadessa Marcello Tucci Wu-Chou Su Alastair Greystoke Ying-Chun Shen Matteo Perrino Yingwen Dong Laure Loumagne Lucie Lépine |
| author_facet | Rui Wang Antoine Italiano Shubham Pant Johann De Bono Todd M Bauer Christophe Massard Chia-Chi Lin Roberto Iacovelli Martin Gutierrez Mansoor Saleh Helen Lee Gennaro Daniele Paolo Andrea Zucali Marielle Chiron Bradley C Carthon Robin Meng Giovanni Abbadessa Marcello Tucci Wu-Chou Su Alastair Greystoke Ying-Chun Shen Matteo Perrino Yingwen Dong Laure Loumagne Lucie Lépine |
| author_sort | Rui Wang |
| collection | DOAJ |
| first_indexed | 2024-04-11T18:10:54Z |
| format | Article |
| id | doaj.art-77a4d7bd1ff24db7bd8825f9ede35742 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-04-11T18:10:54Z |
| publishDate | 2022-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-77a4d7bd1ff24db7bd8825f9ede357422022-12-22T04:10:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-01-0110110.1136/jitc-2021-003697Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter studyRui Wang0Antoine Italiano1Shubham Pant2Johann De Bono3Todd M Bauer4Christophe Massard5Chia-Chi Lin6Roberto Iacovelli7Martin Gutierrez8Mansoor Saleh9Helen Lee10Gennaro Daniele11Paolo Andrea Zucali12Marielle Chiron13Bradley C Carthon14Robin Meng15Giovanni Abbadessa16Marcello Tucci17Wu-Chou Su18Alastair Greystoke19Ying-Chun Shen20Matteo Perrino21Yingwen Dong22Laure Loumagne23Lucie Lépine24Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China10 Department of Medical Oncology, Institute Bergonie, Bordeaux, Aquitaine, FranceDepartment of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USAInstitute of Cancer Research, London, UKAff5 0000 0004 0459 5478grid.419513.bSarah Cannon Research Institute/Tennessee Oncology, PLLC 37203 Nashville TN USA5Institut de Cancérologie Gustave Roussy, Villejuif, France4 National Taiwan University Hospital, Taipei, Taiwan3 Department of Oncology, Catholic University of the Sacred Heart, “Agostino Gemelli” School of Medicine, Rome, Italy, Rome, ItalyHackensack University Medical Center, Hackensack, New Jersey, USADepartment of Medicine, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, USA2Royal National Institute of Blind People, London, UKDirezione Scientifica, Fondazione Policlinico Universitario A Gemelli IRCCS, Roma, ItalyDepartment of Oncology, Humanitas Clinical and Research Center, IRCCS, Milan, ItalyTranslational and Experimental Medicine, Sanofi Research & Development, Vitry-sur-Seine, FranceWinship Cancer Institute of Emory University, Atlanta, Georgia, USA1Sanofi, Cambridge, USA1Sanofi, Cambridge, USA12 Division of Oncology, Cardinal Massaia Hospital, Asti, ItalyDivision of Oncology, Department of Internal Medicine, National Cheng Kung University College of Medicine, Tainan, TaiwanNewcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UKDepartment of Oncology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Biomedical Sciences, IRCCS Istituto Clinico Humanitas, Rozzano, ItalyBiostatistics Oncology Late Phase, Sanofi, Cambridge, Massachusetts, USATranslational Medicine, Sanofi-Aventis, Paris, FrancePharmacokinetics, Excelya on behalf of Sanofi, Alfortville, Francehttps://jitc.bmj.com/content/10/1/e003697.full |
| spellingShingle | Rui Wang Antoine Italiano Shubham Pant Johann De Bono Todd M Bauer Christophe Massard Chia-Chi Lin Roberto Iacovelli Martin Gutierrez Mansoor Saleh Helen Lee Gennaro Daniele Paolo Andrea Zucali Marielle Chiron Bradley C Carthon Robin Meng Giovanni Abbadessa Marcello Tucci Wu-Chou Su Alastair Greystoke Ying-Chun Shen Matteo Perrino Yingwen Dong Laure Loumagne Lucie Lépine Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study Journal for ImmunoTherapy of Cancer |
| title | Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study |
| title_full | Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study |
| title_fullStr | Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study |
| title_full_unstemmed | Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study |
| title_short | Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study |
| title_sort | targeting cd38 and pd 1 with isatuximab plus cemiplimab in patients with advanced solid malignancies results from a phase i ii open label multicenter study |
| url | https://jitc.bmj.com/content/10/1/e003697.full |
| work_keys_str_mv | AT ruiwang targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT antoineitaliano targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT shubhampant targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT johanndebono targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT toddmbauer targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT christophemassard targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT chiachilin targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT robertoiacovelli targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT martingutierrez targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT mansoorsaleh targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT helenlee targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT gennarodaniele targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT paoloandreazucali targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT mariellechiron targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT bradleyccarthon targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT robinmeng targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT giovanniabbadessa targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT marcellotucci targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT wuchousu targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT alastairgreystoke targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT yingchunshen targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT matteoperrino targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT yingwendong targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT laureloumagne targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy AT lucielepine targetingcd38andpd1withisatuximabpluscemiplimabinpatientswithadvancedsolidmalignanciesresultsfromaphaseiiiopenlabelmulticenterstudy |